Zanubrutinib

Contraindicated

Zanubrutinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Zanubrutinib Relugolix Orgovyx Explained Increased relugolix exposure Details Zanubrutinib Apixaban Eliquis Explained An increased risk of bleeding Details Zanubrutinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Zanubrutinib Aspirin Acuprin® An increased risk of bleeding Details Zanubrutinib Aspirin Rectal Aspirin An increased risk of bleeding Details Zanubrutinib Atogepant Qulipta Reduced atogepant exposure Details Zanubrutinib Betrixaban Bevyxxa® An increased risk of bleeding Details Zanubrutinib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Zanubrutinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Zanubrutinib Anagrelide Agrylin An increased risk of bleeding Details Zanubrutinib Clopidogrel Plavix Increased clopidogrel active metabolite exposure, an increased risk of platelet inhibition and an increased risk of bleeding Details Zanubrutinib Cyclosporine Injection Atopica Increased zanubrutinib exposure, an increased risk of zanubrutinib toxicity and an increased cycloSPORINE exposure Details Zanubrutinib Cyclosporine Ophthalmic Cequa Increased zanubrutinib exposure, an increased risk of zanubrutinib toxicity and an increased cycloSPORINE exposure Details Zanubrutinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Zanubrutinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Zanubrutinib Dalteparin Injection Fragmin An increased risk of bleeding Details Zanubrutinib Digoxin Cardoxin® Increased digoxin exposure Details Zanubrutinib Dipyridamole Permole® An increased risk of bleeding Details Zanubrutinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Zanubrutinib Edoxaban Savaysa An increased risk of bleeding Details Zanubrutinib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Zanubrutinib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Zanubrutinib Enoxaparin Lovenox An increased risk of bleeding Details Zanubrutinib Enoxaparin Injection Lovenox An increased risk of bleeding Details Zanubrutinib Fentanyl Transdermal Patch Duragesic® Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Zanubrutinib Fondaparinux Arixtra An increased risk of bleeding Details Zanubrutinib Fondaparinux Injection Arixtra An increased risk of bleeding Details Zanubrutinib Heparin An increased risk of bleeding Details Zanubrutinib Heparin Injection Lipo-Hepin® An increased risk of bleeding Details Zanubrutinib Ketoconazole Topical Extina® Foam Increased zanubrutinib exposure and increased risk of zanubrutinib toxicity Details Zanubrutinib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Zanubrutinib Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Zanubrutinib Lenacapavir Injection Sunlenca Increased zanubrutinib exposure and an increased risk of zanubrutinib-related toxicity Details Zanubrutinib Lenacapavir Oral Sunlenca Increased zanubrutinib exposure and an increased risk of zanubrutinib-related toxicity Details Zanubrutinib Letermovir Injection Prevymis Increased zanubrutinib exposure and an increased risk of zanubrutinib-related toxicity Details Zanubrutinib Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Zanubrutinib Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Zanubrutinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Zanubrutinib Lumateperone Caplyta Reduced lumateperone exposure Details